Kojin Therapeutics Funding: $60M Raised, Series A (2021)
Kojin Therapeutics is based in Cambridge, Massachusetts. It has raised $60M in total funding. Latest round: Series A.
Kojin Therapeutics funding overview
Kojin Therapeutics is based in Cambridge, Massachusetts. Kojin Therapeutics has raised $60M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in June 2021. The round record for Kojin Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie, Eventide Asset Management and 2 others. 8 distinct backers are named across the disclosed rounds.
Kojin Therapeutics at a glance
Total raised
$60M
Latest round
Series A
Latest round date
June 2021
Headquarters
Cambridge, Massachusetts
Notable investors
Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, Dana-Farber Cancer Institute’s Binney Street Capital
Frequently asked about Kojin Therapeutics funding
How much has Kojin Therapeutics raised?
Kojin Therapeutics has raised $60M in total disclosed funding across the rounds on record.
Who has invested in Kojin Therapeutics?
Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie, Eventide Asset Management are named among the investors backing Kojin Therapeutics.
What was the latest Kojin Therapeutics funding round?
The most recent disclosed round is a Series A, announced in June 2021.
Where is Kojin Therapeutics based?
Kojin Therapeutics is based in Cambridge, Massachusetts.
When did Kojin Therapeutics last raise?
The last disclosed Kojin Therapeutics round closed in June 2021 at Series A.
Kojin Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Cambridge below to benchmark round size and investor mix.
